All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.

The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in AUD patients.

"We are pleased to have successfully completed treatment for all participants in Part A of the study, fully aligned with the clinical protocol," said Adi Zuloff‑Shani, PhD, CEO of Clearmind. "This achievement reflects the dedication of our clinical teams and the value of our partnerships with world‑class research centers across the United States and Israel. With data review now underway, we are eager to progress to the next phase of development and continue advancing CMND‑100 as a promising therapeutic candidate for Alcohol Use Disorder."

The multicenter trial is being conducted under FDA oversight, at leading sites in the United States and Israel, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center.